Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-05-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2012-11-466938PMID 23543457PMCID PMC3656452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Sensitive and Quantitative Polymerase Chain Reaction-Based Cell Free In Vitro Non-Homologous End Joining Assay for Hematopoietic Stem Cells

  2012cited by this paper
• Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.

  2012cited by this paper
• Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

  2012cited by this paper
• BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation

  2012cited by this paper
• Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.

  2011cited by this paper
• CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

  2011cited by this paper
• Suboptimal Responses in Chronic Myeloid Leukemia

  2011cited by this paper
• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

  2011cited by this paper
• Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.

  2011cited by this paper
• Advances in the treatment of chronic myeloid leukemia

  2011cited by this paper
• Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.

  2011cited by this paper
• Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

  2011cited by this paper
• Do we have to kill the last CML cell?

  2011cited by this paper
• A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

  2011cited by this paper
• Expression patterns of microRNAs associated with CML phases and their disease related targets

  2011cited by this paper
• Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment

  2010cited by this paper
• A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia.

  2010cited by this paper
• SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

  2010cited by this paper
• Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis.

  2010cited by this paper
• Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

  2010cited by this paper
• Hematopoietic stem cell: self‐renewal versus differentiation

  2010cited by this paper
• Chronic myeloid leukemia: mechanisms of blastic transformation.

  2010cited by this paper
• BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

  2010cited by this paper
• A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6

  2009cited by this paper
• PAK Signaling in Oncogenesis

  2009cited by this paper
• Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.

  2009cited by this paper
• Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

  2008cited by this paper
• BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

  2008cited by this paper
• Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis

  2008cited by this paper
• An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

  2008cited by this paper
• BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress

  2008cited by this paper
• Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

  2007cited by this paper
• Chronic myeloid leukaemia as a model of disease evolution in human cancer

  2007cited by this paper
• Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression

  2007cited by this paper
• Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

  2006cited by this paper
• Gene expression changes associated with progression and response in chronic myeloid leukemia.

  2006cited by this paper
• Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

  2006cited by this paper
• BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

  2006cited by this paper
• BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia: Not Quite Enough to Cause Resistance to Imatinib Therapy?

  2005cited by this paper
• Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

  2005cited by this paper
• Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

  2005cited by this paper
• High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

  2005cited by this paper
• Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.

  2005cited by this paper
• BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

  2004cited by this paper
• β-actin is required for mitochondria clustering and ROS generation in TNF-induced, caspase-independent cell death

  2004cited by this paper
• BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

  2004cited by this paper
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

  2004cited by this paper
• Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia.

  2004cited by this paper
• Radical causes of cancer

  2003cited by this paper
• Oxidative DNA damage: mechanisms, mutation, and disease

  2003cited by this paper
• Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia

  2002cited by this paper
• Hematopoietic growth factors signal through the formation of reactive oxygen species.

  1999cited by this paper
• Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics

  1999cited by this paper
• p53 in chronic myelogenous leukemia in acute phase.

  1991cited by this paper

• Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and Survivorship.

  2026cites this paper
• CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors

  2025cites this paper
• A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway

  2025cites this paper
• Impact of sex chromosome abnormalities in male chronic myeloid leukemia patients

  2024cites this paper
• BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?

  2024cites this paper
• N6-methyladenosine (m6A) RNA modification in chronic myeloid leukemia: unveiling a novel therapeutic target

  2024cites this paper
• Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

  2024cites this paper
• Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation

  2024cites this paper
• Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response

  2024cites this paper
• Circular RNA SPECC1 promoted tumorigenesis and osimertinib resistance in lung adenocarcinoma via a circular RNA-microRNA network

  2024cites this paper
• Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs)

  2023cites this paper
• A Deeply Quiescent Subset of CML LSC Depend on FAO Yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.

  2023cites this paper
• Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors

  2023cites this paper
• The Interplay between Dysregulated Metabolism and Epigenetics in Cancer

  2023cites this paper
• Unifying targeted therapy for leukemia in the era of PARP inhibition.

  2023cites this paper
• Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

  2023cites this paper
• Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention

  2023cites this paper
• DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients

  2023cites this paper
• NOX Dependent ROS Generation and Cell Metabolism

  2023cites this paper
• The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation

  2022cites this paper
• Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia

  2022cites this paper
• Modeling Global Genomic Instability in Chronic Myeloid Leukemia (CML) Using Patient-Derived Induced Pluripotent Stem Cells (iPSCs)

  2022cites this paper
• Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias

  2022cites this paper
• Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy

  2022cites this paper
• Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects

  2022cites this paper
• Perspective Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.

  2022cites this paper
• Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms

  2022cites this paper
• p21-Activated kinases as promising therapeutic targets in hematological malignancies

  2021cites this paper
• Imatinib: The First-Line CML Therapy

  2021cites this paper
• Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors.

  2021cites this paper
• Reactive oxygen species: Role in carcinogenesis, cancer cell signaling and tumor progression.

  2021cites this paper
• Oncogene-independent resistance in Philadelphia chromosome - positive (Ph+) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway

  2021cites this paper
• Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

  2021cites this paper
• Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia

  2021cites this paper
• TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

  2021cites this paper
• The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML

  2020cites this paper
• Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.

  2020cites this paper
• NOX2-Derived Reactive Oxygen Species in Cancer

  2020cites this paper
• Cancer Nanomedicine: Special Focus on Cancer Immunotherapy

  2020cites this paper
• TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.

  2020cites this paper
• Differential Regulation of Telomeric Complex by BCR-ABL1 Kinase in Human Cellular Models of Chronic Myeloid Leukemia—From Single Cell Analysis to Next-Generation Sequencing

  2020cites this paper
• Role of inflammation in the biology of myeloproliferative neoplasms.

  2020cites this paper
• Oxidative resistance of leukemic stem cells and oxidative damage to hematopoietic stem cells under pro-oxidative therapy

  2020cites this paper
• Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients

  2020cites this paper
• Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms

  2019cites this paper
• Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling

  2019cites this paper
• PTBP2 exon 10 inclusion is associated with the progression of CML and it is BCR-ABL1 dependent.

  2019cites this paper
• Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.

  2019cites this paper
• Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

  2019cites this paper
• Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

  2019cites this paper
• Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.

  2019cites this paper
• Ubiquitination is not omnipresent in myeloid leukemia

  2019cites this paper
• Six-packed antibodies punch better

  2019cites this paper
• Relationship of oxidative stress in the resistance to imatinib in Tunisian patients with chronic myeloid leukemia: A retrospective study

  2019cites this paper
• Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells

  2019cites this paper
• Functional polymorphism in the 3’UTR of IKZF1 with risk of childhood acute lymphoblastic leukemia in a Chinese population

  2019cites this paper
• Auto-Commentary on: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

  2018cites this paper
• Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia

  2018cites this paper
• Autophagy and mitochondrial metabolism: insights into their role and therapeutic potential in chronic myeloid leukaemia

  2018cites this paper
• Targeting autophagy in chronic myeloid leukemia through inhibition of the core autophagy protein ATG4B

  2018cites this paper
• Genotoxicity associated with the use of tyrosine kinase inhibitors in patients with chronic myeloid leukemia

  2018cites this paper
• Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT 3 ( ITD )-positive leukemia cells to PARP 1 inhibitors Short title : FLT 3 and PARP 1 inhibitors against AMLs

  2018cites this paper
• Role of NOX2 for leukaemic expansion in a murine model of BCR‐ABL1+ leukaemia

  2018cites this paper
• Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

  2018cites this paper
• PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions

  2018cites this paper
• Redox reactions in cancer: impact and regulation

  2018influential citation
• Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells

  2018cites this paper
• Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia.

  2017cites this paper
• Imatinib: Basic Results

  2017cites this paper
• Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

  2017cites this paper
• Instabilité génétique au cours de la leucémie myéloïde chronique et son implication dans la résistance aux inhibiteurs de tyrosine kinase

  2017cites this paper
• Preclinical approaches in chronic myeloid leukemia: from cells to systems

  2017cites this paper
• Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells

  2017influential citation
• The chronic myeloid leukemia stem cell: stemming the tide of persistence.

  2017cites this paper
• CBP/Catenin antagonists: Targeting LSCs' Achilles heel.

  2017cites this paper
• IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors

  2017cites this paper
• BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro

  2017cites this paper
• Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

  2017cites this paper
• Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.

  2017cites this paper
• Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.

  2017cites this paper
• Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

  2017cites this paper
• Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses

  2017cites this paper
• MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

  2017cites this paper
• Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia

  2016influential citation
• Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

  2016cites this paper
• Recommendations for the Management of CML in the Era of Second-Generation TKIs

  2016cites this paper
• Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  2016cites this paper
• Reactive oxygen species in BCR-ABL 1-expressing cells – relevance to chronic myeloid leukemia

  2016cites this paper
• Mtss1 is a critical epigenetically regulated tumor suppressor in CML

  2016cites this paper
• Depression accelerates the development of gastric cancer through reactive oxygen species‑activated ABL1 (Review).

  2016cites this paper
• Normal ABL 1 is a Tumor Suppressor and Therapeutic Target in Human and Mouse Leukemias Expressing Oncogenic ABL 1 kinases Short title : ABL 1 is a tumor suppressor and therapeutic target

  2016cites this paper
• Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia

  2016cites this paper
• New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.

  2016cites this paper
• Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases

  2016cites this paper
• c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia

  2016cites this paper
• Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

  2015cites this paper
• ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid Malignancies

  2015cites this paper
• Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach

  2015cites this paper
• Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.

  2015cites this paper
• Do we need more drugs for chronic myeloid leukemia?

  2015cites this paper